Radioactive drug takes on standard therapy for rare lung and thymus cancers
NCT ID NCT05918302
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether a radioactive drug called 177Lu-edotreotide works better than the standard drug everolimus for people with advanced neuroendocrine tumors of the lung or thymus. About 170 participants will receive either six cycles of the radioactive therapy or daily everolimus pills. The main goal is to see which treatment delays tumor growth longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-edotreotide (a radioactive drug) and everolimus (a targeted therapy)
- What this could lead to
- If successful, this could provide a more effective treatment option for people with advanced neuroendocrine tumors of the lung or thymus, potentially delaying tumor growth.
- What could go wrong
- This is a Phase 3 trial, but results are not yet known. The experimental therapy involves radiation and may have side effects. It may not prove superior to the existing drug everolimus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AOU Consorziale Policlinico di Bari - CROB Referrall Cancer Center of Basilicata
RECRUITINGBari, 70124, Italy
-
Antwerp University Hospital (UZA)
RECRUITINGEdegem, Edegem, 2650, Belgium
-
Azienda Ospedaliera Universitaria Integrata Verona
RECRUITINGVerona, 37126, Italy
-
Azienda USL IRCCS Di Reggio Emilia
RECRUITINGReggio Emilia, Reggio Emilia, 42123, Italy
-
CHU Liège
RECRUITINGLiège, 4000, Belgium
-
Centre Hospitalier Universitaire (CHU) Bordeux
RECRUITINGBourdeaux, 33000, France
-
Centre Hospitalier Universitaire de Nantes
RECRUITINGNantes, 44000, France
-
Complexo Hospitalario Universitario de Santiago de Compostela
RECRUITINGSantiago de Compostela, Galicia, 28042, Spain
-
Department of Digestive Oncology, CHU Saint Eloi, Montpellier, France/ ICM Cancer Institute at Montpellier
RECRUITINGMontpellier, 34090, France
-
Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, France
RECRUITINGMarseille, 13005, France
-
Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence Rome, Rome, Italy.
NOT_YET_RECRUITINGRoma, 00189, Italy
-
Fundación Jiménez Díaz University Hospital
RECRUITINGMadrid, Madrid, 28040, Spain
-
Hospital Center University Dijon Bourgogne (CHU Bourgogne)
RECRUITINGDijon, Dijon, 21079, France
-
Hospital General Universitario Gregorio Marañón
RECRUITINGMadrid, Madrid, 28007, Spain
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, Madrid, 28041, Spain
-
Hospital Universitario Central de Asturias
RECRUITINGOviedo, Principality of Asturias, 33011, Spain
-
Hospital Universitario Ramón y Cajal, Madrid
RECRUITINGMadrid, Madrid, 28034, Spain
-
Hospital Universitario Virgen del Rocío
RECRUITINGSeville, Andalusia, 41013, Spain
-
Hospital Universitario y Politécnico La Fe
RECRUITINGValencia, Valencia, 46026, Spain
-
Hôpital Edouard Herriot, Lyon
RECRUITINGLyon, 69003, France
-
I. Gustave Roussy, Paris
RECRUITINGParis, 94805, France
-
ICO Institut Català d'Oncologia L'Hospitalet
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Irsì - Meldola
RECRUITINGMeldola, 47014, Italy
-
Istituto Europeo di Oncologia - Milano
RECRUITINGMilan, 20141, Italy
-
Lille University Hospital
RECRUITINGLille, 59000, France
-
UCL Saint-Luc
RECRUITINGBrussels, 1200, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation